JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
Ipamorelin is a research compound studied in cell-based assay formats for its selective GHSR-1a (growth hormone secretagogue receptor-1a) activity. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. This synthetic pentapeptide demonstrates distinct pharmacological properties in receptor binding studies and cellular signalling assays relevant to growth hormone axis research.
Ipamorelin acts via selective GHSR-1a activation, a class A G-protein coupled receptor predominantly linked to Gq/11 signalling pathways. Competitive radioligand binding assays demonstrate high selectivity for GHSR-1a over other growth hormone secretagogue receptor subtypes. Binding kinetic studies reveal KD values in the nanomolar range, indicating strong receptor affinity in transfected cell systems expressing recombinant GHSR-1a.
Saturation binding experiments using [35S]GTPγS binding assays show concentration-dependent receptor activation with EC50 values typically ranging from 1-10 nM in various cell model systems. The compound exhibits minimal cross-reactivity with related peptide hormone receptors, including ghrelin receptor variants and other GPCR families, as demonstrated through selectivity screening panels.
Following GHSR-1a engagement, ipamorelin initiates classical Gq/11-mediated signalling cascades. Calcium mobilisation assays using fluorescent indicator dyes reveal rapid intracellular Ca2+ elevation within seconds of peptide application. This response demonstrates typical GPCR kinetics with peak calcium release occurring at 10-30 seconds post-stimulation in responsive cell lines.
Phospholipase C activation represents a key downstream effector mechanism. Inositol phosphate accumulation assays show dose-dependent IP3 formation following ipamorelin treatment in GHSR-1a-expressing cells. Additionally, protein kinase C activation occurs through diacylglycerol generation, as evidenced by PKC translocation studies using fluorescently-tagged enzyme constructs.
Pituitary somatotroph cell cultures provide physiologically relevant model systems for ipamorelin research. Primary rat anterior pituitary cells maintain endogenous GHSR-1a expression and demonstrate robust responses to ipamorelin stimulation. These cultures exhibit concentration-dependent growth hormone release patterns measurable through enzyme-linked immunosorbent assays.
Hypothalamic arcuate nucleus neurons represent another valuable primary cell model, particularly for studying upstream regulatory mechanisms. These cells express native GHSR-1a and demonstrate electrophysiological responses to ipamorelin application, including altered firing patterns and membrane potential changes detectable through patch-clamp techniques.
HEK293 cells stably transfected with human GHSR-1a provide standardised platforms for receptor pharmacology studies. These systems offer consistent receptor expression levels and reproducible assay conditions. CHO-K1 cells expressing recombinant GHSR-1a serve as alternative model systems, particularly useful for binding kinetic analyses and high-throughput screening applications.
In vitro stability assays reveal ipamorelin's resistance to common peptidases compared to endogenous ghrelin. Mass spectrometry analysis of peptide degradation products in serum-containing media demonstrates extended half-life characteristics. This stability profile contributes to sustained receptor engagement in cell culture systems.
Enzymatic degradation studies using purified peptidase preparations identify specific cleavage sites and degradation pathways. These analyses inform optimal storage conditions and assay design parameters for consistent experimental results.
Prolonged ipamorelin exposure in cell model systems reveals receptor desensitisation patterns typical of GPCR activation. Beta-arrestin recruitment assays demonstrate time-dependent receptor internalisation following sustained peptide stimulation. Recovery kinetics studies show receptor resensitisation occurs over 2-4 hour periods in most cell model systems.
Research using aged cell culture models reveals altered GHSR-1a expression patterns and modified signalling responses. Senescent cell populations demonstrate reduced receptor density and attenuated calcium mobilisation responses to ipamorelin stimulation. These findings provide cellular basis for understanding age-related changes in growth hormone axis responsiveness.
Ipamorelin demonstrates selective GHSR-1a activation with nanomolar binding affinity and robust intracellular signalling responses in various cell model systems. The compound initiates classical Gq/11 pathways leading to calcium mobilisation and downstream effector activation. Primary pituitary cultures and transfected cell lines provide valuable platforms for mechanistic studies, while enzymatic stability analyses reveal favourable degradation profiles. Age-related cellular models offer insights into altered receptor pharmacology patterns, supporting continued research into growth hormone axis modulation mechanisms.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
Forgot password?
Country: United States (US-only registration)
All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.